← Eichor
Study identifier: NCT06766435 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Evaluation of the Abbott i-STAT TBI Biomarker Test

Condition: Traumatic Brain Injury  ·  Sponsor: Icahn School of Medicine at Mount Sinai

PhaseNA
Planned participants450
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

According to the Centers for Disease Control and Prevention, approximately 200,000 hospitalizations occurred in 2020 related to Traumatic Brain Injury (TBI), which does not include many TBIs treated only in emergency departments, urgent care, primary care, or that are not evaluated by a clinician. Head CT is a critical component of care for severe TBI, however in mild TBI there is practice variation with a wider risk to benefit estimation for obtaining head CT imaging. Potential disadvantages of head CT include longer Emergency Department (ED) length of stay (LOS), higher costs, and diagnostic radiation exposure. The i-STAT TBI test is a panel of in vitro diagnostic immunoassays for the quantitative measurements of glial fibrillary acidic protein (GFAP) and ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1) in whole blood and a semi-quantitative interpretation of test results derived from these measurements, using the i-STAT Alinity instrument. This biomarker test is cleared for use in adults with mild TBI (Glasgow Coma Scale 13-15) within 24 hours of injury, to aid in determining the need for head CT imaging. Currently, CT head imaging for adults with suspected mild TBI is obtained based on clinicians' usual practice patterns and beliefs about patient expectations. Prior research has demonstrated the blood TBI test may reduce unnecessary CT scans by up to 40%, however the impact on head CT ordering has not yet been studied prospectively. It is important to understand the exte…

This description comes directly from the study's public registry record.

Talk to the study team

Mitali Pradhan, MS, CCRP  ·  201-423-3585  ·  Mitali.Pradhan@mountsinai.org

Jonathan Schimmel, MD  ·  jonathan.schimmel@mountsinai.org

Always discuss trial participation with your own doctor first.

Locations (3)

Mount Sinai MorningsideNew York, New York, United StatesRecruiting
Mount Sinai HospitalNew York, New York, United StatesRecruiting
Mount Sinai WestNew York, New York, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06766435